Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term p53. Found 51 abstracts

no pagination
Sementino E, Menges CW, Kadariya Y, Peri S, Xu J, Liu Z, Wilkes RG, Cai KQ, Rauscher FJ, Klein-Szanto AJ, Testa JR. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. Journal of cellular physiology. 2018 Nov;233(11):8952-61.   PMCID: PMC6168364
Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK, Wang X, Bell DA, Li X, Garlick DS, Liu Q, Hollstein M, George DL, Murphy ME. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes & development. 2016 Apr 15;30(8):918-30.   PMCID: 4840298
Maluchenko NV, Chang HW, Kozinova MT, Valieva ME, Gerasimova NS, Kitashov AV, Kirpichnikov MP, Georgiev PG, Studitsky VM. [Inhibiting the pro-tumor and transcription factor FACT: Mechanisms]. Mol Biol (Mosk). 2016 Jul;50(4):599-610.
Maluchenko NV, Chang HW, Kozinova MT, Valieva ME, Gerasimova NS, Kitashov AV, Kirpichnikov MP, Georgiev PG, Studitsky VM. [Inhibiting the pro-tumor and transcription factor FACT: Mechanisms]. Mol Biol (Mosk). 2016 Jul;50(4):599-610.
Bodurka DC, Deavers MT, Tian CQ, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system. Cancer. 2012 Jun;118(12):3087-94.   PMCID: *
Natsuizaka M, Naganuma S, Kagawa S, Ohashi S, Ahmadi A, Subramanian H, Chang S, Nakagawa KJ, Ji XJ, Liebhaber SA, Klein-Szanto AJ, Nakagawa H. Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF-1 alpha-mediated mRNA transcription and continuous protein synthesis. Faseb Journal. 2012 Jun;26(6):2620-30.   PMCID: PMC3360153
Rao SY, Lee SY, Gutierrez A, Perrigoue J, Thapa RJ, Tu ZG, Jeffers JR, Rhodes M, Anderson S, Oravecz T, Hunger SP, Timakhov RA, Zhang RG, Balachandran S, Zambetti GP, Testa JR, Look AT, Wiest DL. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood. 2012 Nov;120(18):3764-73.   PMCID: PMC3488889
Frank AK, Pietsch EC, Dumont P, Tao J, Murphy ME. Wild-type and mutant p53 proteins interact with mitochondrial caspase-3. Cancer Biology & Therapy. 2011 Apr;11(8):740-5.   PMCID: PMC3100564
Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, McBryan T, Doyle B, McKay C, Oien KA, Enders GH, Zhang RG, Sansom OJ, Adams PD. Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis. Mol Cell. 2011 Apr;42(1):36-49.
Kung CP, Budina A, Balaburski G, Bergenstock MK, Murphy ME. Autophagy in Tumor Suppression and Cancer Therapy. Critical Reviews in Eukaryotic Gene Expression. 2011 Jan;21(1):71-100.   PMCID: PMC3187613
Pimkina JS, Murphy ME. Interaction of the ARF tumor suppressor with cytosolic HSP70 contributes to its autophagy function. Cancer Biology & Therapy. 2011 Sep;12(6):503-9.   PMCID: PMC3218591
Dominguez-Brauer C, Brauer PM, Chen YJ, Pimkina J, Raychaudhuri P. Tumor suppression by ARF Gatekeeper and caretaker. Cell cycle (Georgetown, Tex). 2010 Jan;9(1):86-9.   PMCID: *
Natsuizaka M, Ohashi S, Wong GS, Ahmadi A, Kalman RA, Budo D, Klein-Szanto AJ, Herlyn M, Diehl JA, Nakagawa H. Insulin-like growth factor-binding protein-3 promotes transforming growth factor-beta 1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis. 2010 Aug;31(8):1344-53.   PMCID: PMCID: PMC2915630 [Available on 2011/8/1]
Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, Robson ME, Offit K, Barakat RR, Boyd J. Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma. Plos One. 2010 Apr;5(4).   PMCID: PMCID: PMC2859950
Dominguez-Brauer C, Chen YJ, Brauer PM, Pimkina J, Raychaudhuri P. ARF stimulates XPC to trigger nucleotide excision repair by regulating the repressor complex of E2F4. EMBO reports. 2009 Sep;10(9):1036-42.   PMCID: PMC2570060
Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnolia RI, Hendricks D, Bonome T, Farley JH. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008 Dec;111(3):487-95.
Che M, Desilvio M, Pollack A, Grignon DJ, Mohan Venkatesan V, Hanks GE, Sandler HM. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: A study based on RTOG 9202. International Journal of Radiation Oncology Biology Physics. 2007 Nov;69(4):1117-23.
Lee CH, Inoki K, Karbowniczek M, Petroulakis E, Sonenberg N, Henske EP, Guan KL. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO Journal. 2007 Nov;26(23):4812-23.
Mellert H, Sykes SM, Murphy ME, McMahon SB. The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain. Cell cycle (Georgetown, Tex). 2007 Jun;6(11):1304-6.
Pietsch EC, Leu JI, Frank A, Dumont P, George DL, Murphy ME. The tetramerization domain of p53 is required for efficient BAK oligomerization. Cancer Biology & Therapy. 2007 Oct;6(10):1576-83.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term p53

p53 expression apoptosis cancer mitochondria Fact Cbl0137 curaxins CARCINOMA PHOSPHORYLATION APOPTOSIS cancer stem cells Ssrp1 PROTEIN mTOR autophagy in-vivo mutations NF-kappaB and HSF1 mdm2 Spt16 translational control photoproducts isolated rat dna-binding domain dna-repair cells MYC inducible factor (hif)-1-alpha ASSOCIATION RHEB pten expression PROTEIN-KINASE gene-expression progression ACTIVATION analysis surface epithelium beta tgf-beta PLATINUM-BASED CHEMOTHERAPY p19(arf) tumor-suppressor p19ARF pro-caspase-3 responsive element breast-cancer bcl-x-l GENE-MUTATIONS IN-VIVO 1981 ole b-v90-p665 HSP70 CDKN2A target sites RTOG 9202 tuberous sclerosis tumorigenesis mutational TRANSCRIPTION gene DEATH dna-damage Androgen deprivation and radiotherapy 1989 donnell tj-v57-p79 RAPAMYCIN e-cadherin pathogenesis internal ribosome entry site cap-dependent translation 1989 ser a-v129-p740 Ser46 phosphorylation metabolism p19(arf) ribosome entry NER ARF-XPC-E2F4-p130 growth arrest genomic instability betaine homocysteine methyltransferase IHC down-regulation NUCLEAR ACCUMULATION oncogene breast-cancer cells pathway MAMMALIAN TARGET prophylactic oophorectomy SURVIVAL degradation P53-DEPENDENT APOPTOSIS rapamycin MUTATIONS acetylation Ovarian cancer Prognostic factor TIP60 Overexpression GROWTH p16(ink4a) advanced prostate cancer SUPPRESSES TUMOR-GROWTH phosphatidylinositol GAP ACTIVITY protein conjugation system polymorphism 2008 nida i-v445-p77 ferroptosis HUMAN BREAST-CANCER CISPLATIN-BASED CHEMOTHERAPY lymphoma PROGNOSTIC-SIGNIFICANCE tumor suppressor ARF-E2F4-XPC-DNA repair neoplasms cancer-cells stem-cell universal grading system Immunohistochemistry epithelial-cells nucleotide excision-repair Locally signaling OVER-EXPRESSION TP53 complex BCL-2 PACLITAXEL MITOCHONDRIA Prognostic markers hepatocytes BAK t-cell development brca1 GENE interacting factor-i tumor suppression MDM2 mammalian-cells tumors RADIATION-THERAPY C-MYC xeroderma-pigmentosum INK4A mesothelioma malignant glioma-cells small-molecule inhibitor ADENOCARCINOMA braf gynecologic-oncology-group MUTATION carcinoma GENE-PRODUCTS caspase-3 tumor suppressor
Last updated on Friday, January 03, 2020